Lemonade
LMND
$63.42
-7.58%
Lemonade, Inc. is a technology-driven insurance company that uses artificial intelligence and behavioral economics to offer renters, homeowners, pet, and life insurance policies across the United States and Europe. It positions itself as a disruptor in the property and casualty insurance industry, leveraging a digital-first platform, AI-powered claims processing, and a social impact model to differentiate from traditional insurers. The current investor narrative centers on Lemonade's accelerating revenue growth and improving loss ratio, which signal a path toward profitability, but is tempered by persistent net losses, a high valuation, and a recent analyst downgrade citing valuation concerns after a sharp rally.…
LMND
Lemonade
$63.42
Related headlines
Investment Opinion: Should I buy LMND Today?
Rating: Hold. Lemonade is a high-growth insurtech with accelerating revenue and improving margins, but its premium valuation and lack of profitability warrant caution. The analyst consensus is hold with an average target of $62.78, implying -6.5% downside from the current price of $67.18.
Supporting Evidence: Revenue grew 55% YoY to $234.4M in Q1 2026, gross margin expanded to 43.1% from 26.3% a year ago, and free cash flow turned positive at $19.5M TTM. However, the trailing PS ratio of 6.93x is 362% above the industry average of 1.5x, and the company still reports a net loss of -$35.8M. The stock's beta of 1.785 indicates high volatility, and the year-to-date relative strength vs. S&P 500 is -20.6%.
Risks & Conditions: This Hold would upgrade to Buy if the company achieves GAAP profitability or if the PS ratio compresses below 4x (near historical lows). It would downgrade to Sell if revenue growth decelerates below 30% or if net losses widen. The stock appears overvalued relative to industry peers but fairly valued relative to its own historical PS range of 7.1x to 238.4x, given its current 6.93x is near the low end.
Sign up to view all
LMND 12-Month Price Forecast
Lemonade's strong growth and improving margins are offset by a high valuation and lack of profitability. The base case of continued improvement but no profitability in 12 months is most likely, leading to a neutral stance. If the company can achieve positive net income sooner than expected, the stance would upgrade to bullish. Conversely, if growth decelerates sharply or losses widen, a bearish stance would be warranted. The current risk/reward is balanced, with the stock trading near the low end of its historical PS range but still expensive vs. peers.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Lemonade's 12-month outlook, with a consensus price target around $64.22 and implied upside of +1.3% versus the current price.
Average Target
$64.22
0 analysts
Implied Upside
+1.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$40 - $92
Analyst target range
Lemonade is covered by 9 analysts, with a consensus recommendation of 'hold' (mean rating of 3.0 on a 1-5 scale). The average target price is $62.78, implying a -6.5% downside from the current price of $67.18. The distribution shows a mix of ratings: recent actions include a downgrade from Morgan Stanley to Equal Weight (from Overweight) on July 8, 2026, while Truist Securities maintains a Buy and Citizens rates it Market Outperform. The target price range spans from a low of $40.00 to a high of $92.00. The wide spread of $52.00 indicates high uncertainty about the company's future. The high target of $92.00 assumes continued strong growth and eventual profitability, while the low target of $40.00 prices in margin compression or competitive losses. Recent downgrades from Morgan Stanley and persistent Underperform ratings from Keefe, Bruyette & Woods suggest caution among some analysts, while upgrades from Morgan Stanley in March 2026 show optimism around autonomous vehicle insurance. The mixed sentiment reflects the tension between Lemonade's rapid growth and its ongoing losses.
Drowning in data?
Find the real signal!
Bulls vs Bears: LMND Investment Factors
Lemonade presents a classic high-growth, high-valuation debate. On the bull side, revenue growth accelerating to 55%, gross margin expansion to 43.1%, positive free cash flow, and narrowing net losses provide a compelling path to profitability. On the bear side, the stock remains unprofitable with a -31% ROE, trades at a 362% premium to industry PS ratios, and carries a consensus hold rating with implied downside. The single most important tension is whether the company can sustain its 55% revenue growth while continuing to improve margins to reach GAAP profitability. If growth decelerates or margins stall, the high valuation could compress sharply; if profitability is achieved sooner than expected, the stock could re-rate significantly higher.
Bullish
- Revenue Growth Accelerating to 55%: Q1 2026 revenue grew 55% YoY to $234.4M, up from 24.8% in Q2 2024 and 34.5% in Q3 2024, indicating strong momentum driven by customer growth and product expansion into auto insurance.
- Gross Margin Expansion to 43.1%: Gross margin improved from 26.3% in Q1 2025 to 43.1% in Q1 2026, reflecting better underwriting and scale benefits. This is a critical driver of the path to profitability.
- Positive Free Cash Flow Achieved: Trailing twelve-month free cash flow turned positive at $19.5M, a milestone that suggests the company can fund operations internally and reduces reliance on external capital.
- Net Loss Narrowing Significantly: Net loss improved from -$62.4M in Q1 2025 to -$35.8M in Q1 2026, with net margin improving from -41.3% to -15.3%, showing a clear trajectory toward profitability.
Bearish
- Still Unprofitable with Negative ROE: Despite improvements, Lemonade reported a net loss of -$35.8M in Q1 2026 and a return on equity of -31.0%, indicating the company has not yet reached sustainable profitability.
- High Valuation vs. Industry Peers: Trailing PS ratio of 6.93x is 362% above the property & casualty insurance industry average of ~1.5x, leaving little room for error if growth decelerates.
- Analyst Consensus Hold with Downside: Average analyst target of $62.78 implies -6.5% downside from current price of $67.18, and recent downgrade from Morgan Stanley on July 8, 2026 highlights valuation concerns after a 50% rally.
- High Beta and Volatility Risk: Beta of 1.785 means the stock is 78.5% more volatile than the market, amplifying downside in market downturns. The 52-week range of $35.70 to $99.90 shows extreme price swings.
LMND Technical Analysis
Lemonade's stock has experienced a volatile but overall strong uptrend over the past year, with a 1-year price change of +64.9%, significantly outperforming the S&P 500's +18.4%. The current price of $67.18 sits at 50.2% of its 52-week range ($35.70 to $99.90), indicating the stock is in the middle of its range after recovering from a low of $35.70. This positioning suggests the stock is neither overextended nor at a deep value level, but rather in a consolidation phase following a substantial rally from its lows. The 1-month price change of +17.3% shows strong short-term momentum, while the 3-month change of -5.3% indicates a pullback from higher levels, creating a divergence with the longer-term uptrend. This divergence could signal a temporary pause or mean reversion, especially given the stock's beta of 1.785, which implies 78.5% more volatility than the market. The 52-week high of $99.90 acts as key resistance; a breakout above this level would signal a resumption of the uptrend, while a breakdown below the 52-week low of $35.70 would indicate a bearish reversal. The stock's high beta means it amplifies market moves, requiring careful risk management.
Beta
1.78
1.78x market volatility
Max Drawdown
-47.7%
Largest decline past year
52-Week Range
$36-$100
Price range past year
Annual Return
+53.8%
Cumulative gain past year
| Period | LMND Return | S&P 500 |
|---|---|---|
| 1m | +10.3% | +0.4% |
| 3m | -4.1% | +5.5% |
| 6m | -32.0% | +8.4% |
| 1y | +53.8% | +18.9% |
| ytd | -16.5% | +9.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
LMND Fundamental Analysis
Lemonade's revenue trajectory is accelerating strongly, with Q1 2026 revenue of $234.4 million growing 55.0% year-over-year, up from 55.0% in Q1 2025 (which was $151.2 million). This marks a significant acceleration from the 24.8% growth in Q2 2024 and 34.5% in Q3 2024, driven by customer growth and expansion into new products like auto insurance. The company operates in a single reportable segment, so all growth comes from its core insurance operations. Despite the impressive top-line growth, Lemonade remains unprofitable, with a net loss of -$35.8 million in Q1 2026, though this loss narrowed from -$62.4 million in Q1 2025. Gross margin improved to 43.1% in Q1 2026 from 26.3% a year earlier, reflecting better underwriting and scale benefits. The net margin of -15.3% in Q1 2026 is a substantial improvement from -41.3% in Q1 2025, indicating progress toward profitability. Lemonade's balance sheet is healthy with $386.5 million in cash at the end of Q1 2026 and a debt-to-equity ratio of 0.34, indicating low leverage. Free cash flow turned positive at $19.5 million on a trailing twelve-month basis, a critical milestone that suggests the company can fund operations internally. Return on equity remains deeply negative at -31.0%, but the improving cash flow and narrowing losses are positive signs for financial sustainability.
Quarterly Revenue
$234400000.0B
2026-03
Revenue YoY Growth
+55.0%
YoY Comparison
Gross Margin
43.1%
Latest Quarter
Free Cash Flow
$19500001.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is LMND Overvalued?
Since Lemonade has negative net income (net loss of -$35.8 million in Q1 2026), the price-to-sales (PS) ratio is the most appropriate valuation metric. The trailing PS ratio is 6.93x, while the forward PS ratio (based on estimated revenue of $2.61 billion) is approximately 1.96x, implying the market expects significant revenue growth to justify the current price. Compared to the property and casualty insurance industry average PS ratio of roughly 1.5x, Lemonade trades at a 362% premium on a trailing basis, reflecting its high growth but also its lack of profitability. This premium may be justified by Lemonade's 55% revenue growth rate, which far exceeds the industry average of 5-10%. Historically, Lemonade's PS ratio has ranged from 7.1x to 238.4x over the past five years, and the current 6.93x is near the low end of that range, suggesting the stock is relatively cheap compared to its own history. This low historical PS multiple indicates that the market has priced in more conservative expectations, potentially offering a value opportunity if growth continues to accelerate.
PE
-30.9x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-33.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Lemonade's primary financial risk is its persistent unprofitability, with a net loss of -$35.8M in Q1 2026 and a negative ROE of -31.0%. Although free cash flow turned positive at $19.5M TTM, the company still relies on revenue growth to cover operating expenses, which were $135.7M in Q1 2026. The debt-to-equity ratio of 0.34 is low, but any slowdown in growth could pressure margins and delay the path to profitability, potentially requiring additional capital raises. Revenue concentration in a single segment (P&C insurance) adds operational risk if underwriting losses spike.
Market & Competitive Risks: The stock's trailing PS ratio of 6.93x is 362% above the industry average of ~1.5x, making it vulnerable to valuation compression if growth disappoints. With a beta of 1.785, the stock is highly sensitive to market downturns, and the recent Morgan Stanley downgrade on July 8, 2026 citing valuation concerns after a 50% rally highlights this risk. Competitive threats from traditional insurers adopting digital tools and other insurtechs could pressure customer acquisition costs. Regulatory changes in insurance markets across the US and Europe also pose headwinds.
Worst-Case Scenario: In a severe downturn, if revenue growth decelerates below 20% and losses widen due to adverse claims or competitive pressure, the stock could fall to its 52-week low of $35.70, representing a -46.9% decline from the current price of $67.18. This scenario aligns with the analyst low target of $40.00 and would imply a PS ratio closer to 2x, still above industry average but reflecting a loss of confidence in the growth story.
FAQ
The primary risks are: 1) Financial risk: persistent losses with a net loss of -$35.8M in Q1 2026 and negative ROE of -31.0%, though improving. 2) Valuation risk: trailing PS ratio of 6.93x is 362% above the industry average, leaving little margin for error. 3) Competitive risk: traditional insurers and other insurtechs could erode Lemonade's market share or pressure customer acquisition costs. 4) Macro risk: high beta of 1.785 means the stock is highly sensitive to market downturns, and the recent Morgan Stanley downgrade highlights valuation concerns. The most severe risk is a growth deceleration below 30%, which could trigger a re-rating toward the 52-week low of $35.70 (-46.9% downside).
The 12-month outlook is balanced with a base case probability of 50% and a target range of $55-$70, assuming revenue growth moderates to 35-40% and margins continue to improve but remain negative. The bull case (25% probability) targets $80-$92 if the company achieves profitability and the Tesla autonomous vehicle partnership drives growth. The bear case (25% probability) targets $36-$50 if growth disappoints or losses widen. The analyst average target is $62.78, implying -6.5% downside. The most likely scenario is the base case, where the stock trades in a range as the market digests the growth vs. valuation trade-off.
Lemonade's trailing PS ratio of 6.93x is significantly above the property & casualty insurance industry average of ~1.5x, suggesting the stock is overvalued relative to traditional peers. However, compared to its own history, the current PS ratio is near the low end of its 5-year range of 7.1x to 238.4x, indicating it is relatively cheap by its own standards. The forward PS ratio of ~1.96x (based on estimated revenue of $2.61B) is more reasonable but still above the industry average. The market is pricing in expectations of continued high growth (55% YoY) and eventual profitability. If growth sustains, the valuation may be justified; if not, the stock could see significant multiple compression.
Lemonade is a high-growth insurtech with accelerating revenue (55% YoY) and improving margins, but it remains unprofitable with a net loss of -$35.8M in Q1 2026. The analyst consensus is hold, with an average target of $62.78 implying -6.5% downside from the current price of $67.18. The stock trades at a trailing PS ratio of 6.93x, which is 362% above the industry average of 1.5x, but near the low end of its historical range. For long-term growth investors willing to tolerate volatility (beta 1.785) and a lack of near-term profitability, it could be a good buy if they believe the company will achieve profitability within 2-3 years. However, value investors and those seeking income should avoid it. The biggest downside risk is a growth deceleration that compresses the valuation multiple.
Lemonade is better suited for long-term investment (3-5 years) given its high growth but lack of profitability. The stock has a beta of 1.785, making it too volatile for short-term trading unless one has a high risk tolerance and active risk management. The company does not pay a dividend, so total return depends entirely on price appreciation. The improving fundamentals (positive free cash flow, narrowing losses) suggest a path to profitability that could reward patient investors. Short-term traders may find opportunities around earnings announcements, but the stock's high volatility and negative year-to-date relative strength (-20.6% vs. S&P 500) make it risky for short-term holds. A minimum holding period of 3 years is recommended to allow the growth story to play out.
